With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Both Kisunla and Ebglyss hold the potential to become blockbuster drugs. Investors shouldn't overlook Lilly's pipeline, ...

Lilly’s stock has been on a roll this year as it witnessed unparalleled success with sales of Mounjaro and Zepbound. In the ...

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...

Eli Lilly’s Kisunla (donanemab) will not yet be made available to Alzheimer’s patients in the UK after the National Institute ...

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related imaging abnormalities with oedema/effusion (ARIA-E). Lilly announced ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

On Oct. 23, Lilly's drug for Alzheimer's disease, Kisunla, was approved in the U.K. by the Medicines and Healthcare products Regulatory Agency (MHRA), following in the footsteps of regulators at ...